Blockade of IL-17A and its receptor is highly efficacious in the treatment of PsA17,18 and, despite lack of robust efficacy in RA, can induce sustained American College of Rheumatology 50 (ACR50) response in a subset of patients with RA19–21. The gene discussed is IL17A; the disease is rheumatoid arthritis.